Category: Ophthalmology
-
Iolyx and Théa partner on $280 million autoimmune eye drug deal
Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.
-
Circio bolsters data for circVec circular RNA expression platform
New data shows enhanced performance in heart and brain tissues, broadening the platform’s therapeutic potential and boosting gene expression by 50%.
-
AAVantgarde closes $141 million Series B for genetic disease therapies
The company plans to use the Series B funding to progress clinical trials for two genetic eye disorders, Stargardt disease and Usher 1B syndrome.
-
Chiesi scores FDA priority review for rare vision disorder
Raxone is approved for Leber Hereditary Optic Neuropathy (LHON), a rapid vision-loss disease, in multiple countries, including the EU.
-
UK NICE recommends Chiesi’s rare eye therapy
The final draft guidance supports Chiesi’s Raxone for patients aged 12 and above with Leber Hereditary Optic Neuropathy (LHON).
-
Nicox and Kowa sign €191.5 million pact for glaucoma drug
Following the licensing agreement for NCX470, Nicox’s stock rose by 60.6% in market trading.
-
Roche wins FDA nod for label expansion of Susvimo eye implant in DME
The US FDA has approved Roche’s Susvimo, intravitreal ocular implant, for treating diabetic macular edema (DME).
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.